73895-32-6

Basic information

• Product Name: 6-chloro-2-dimethylamino-3-nitropyridine
• Synonyms: 6-chloro-2-dimethylamino-3-nitropyridine
• CAS NO: 73895-32-6
• Molecular Weight: 201.612
• Mol File: 73895-32-6.mol
• Article Data: 4

Chemical Properties

• CAS DataBase Reference: 6-chloro-2-dimethylamino-3-nitropyridine(CAS DataBase Reference)
• NIST Chemistry Reference: 6-chloro-2-dimethylamino-3-nitropyridine(73895-32-6)
• EPA Substance Registry System: 6-chloro-2-dimethylamino-3-nitropyridine(73895-32-6)

Safety Data

• Hazardous Substances Data: 73895-32-6(Hazardous Substances Data)

Upstream product

• 16013-85-7 2,6-dicholoro-3-nitropyridine 
• 124-40-3 dimethyl amine 
• 2402-78-0 2,6-dichloropyridine 
• 506-59-2 N,N-dimethylammonium chloride 

Downstream Products

• 1160932-41-1 2-dimethylamino-6-(4-fluorobenzylamino)-3-nitropyridine 
• 1160932-42-2 2-dimethylamino-6-(4'-fluoro-benzylamino)-3-aminopyridine 
• 252917-24-1 {6-[(2-{[4-(2,4-dichlorophenyl)-5-imidazolylpyrimidin-2-yl]amino}ethyl)amino]-3-nitro(2-pyridyl)}dimethylamine 

Relevant articles and documents

Oxidation potentials of N-modified derivatives of the analgesic flupirtine linked to potassium KV7 channel opening activity but not hepatocyte toxicity

Openers of neuronal voltage-gated potassium channels (KV) are of interest as therapeutic agents for treating pain (flupirtine) and epilepsy (retigabine). In an effort to better understand the mechanisms of action and toxicity of flupirtine, we synthesized nine novel analogues with varying redox behavior. Flupirtine can be oxidatively metabolized into azaquinone di-imines; thus, the oxidation potentials of flupirtine and its analogues were measured by cyclic voltammetry. KV7.2/3 (KCNQ2/3) opening activity was determined by an established assay with HEK293 cells overexpressing these channels. A link was found between the oxidation potentials of the compounds and their EC50 values for potassium channel opening activity. On the other hand, no correlation was observed between oxidation potentials and cytotoxicity in cultures of transgenic mouse hepatocytes (TAMH). These results support the idea that oxidative metabolites of flupirtine contribute to the mechanism of action, similar to what was recently proposed for acetaminophen (paracetamol), but not to hepatotoxicity.

Inhibitors of glycogen synthase kinase 3

New pyrimidine or pyridine based compounds, compositions and methods of inhibiting the activity of glycogen synthase kinase (GSK3) in vitro and of treatment of GSK3 mediated disorders in vivo are provided. The methods, compounds and compositions of the invention may be employed alone, or in combination with other pharmacologically active agents in the treatment of disorders mediated by GSK3 activity, such as diabetes, Alzheimer's disease and other neurodegenerative disorders, obesity, atherosclerotic cardiovascular disease, essential hypertension, polycystic ovary syndrome, syndrome X, ischemia, traumatic brain injury, bipolar disorder, immunodeficiency or cancer.